SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce Holdings is trending as a key beneficiary of global rearmament and surging civil aerospace demand, highlighted by a significant engine order from Delta Air Lines and numerous defense contracts. The community anticipates strong upcoming earnings, fueled by these catalysts and long-term optimism for its small modular reactor (SMR) and power systems solutions for data centers.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet ($STRK) is trending as its ecosystem displays robust growth with record TVL and stablecoin supply, sparking discussion around its ZK-STARKs technology providing quantum resistance and privacy features for institutional adoption. The community remains convicted in its long-term vision as critical infrastructure for Ethereum scaling and BTCFi, further solidified by its token's expansion to Solana.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is trending following its latest earnings report, which, despite beating revenue and EPS, saw future profit guidance trimmed and analyst price targets cut, triggering a sharp sell-off. The community is fiercely debating whether this decline is an overreaction driven by broader 'AI panic' and M&A integration costs, or a justified repricing for an overvalued stock with concerns over declining margins.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion (INFQ) is seeing surging community interest following its NYSE debut and upcoming bell-ringing ceremony, driven by its advanced neutral-atom quantum technology, robust partnerships, and the expectation of increased trading accessibility as initial brokerage platform issues resolve.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending following highly positive Phase 3 trial results for its COMP360 psilocybin therapy in treatment-resistant depression, with the community actively discussing its potential as a first-to-market FDA-approved psychedelic treatment. This enthusiasm is balanced by investor conversations surrounding a proposed public offering and its implications for dilution and future funding.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is a focal point for investors anticipating the imminent BLA resubmission for its Duchenne Muscular Dystrophy therapy, Deramiocel, driven by robust Phase 3 data and increasing institutional ownership, alongside excitement for its promising exosome platform.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending due to heightened buyout speculation, driven by the community's frustration over perceived management silence regarding crucial AUR200 pipeline updates and ongoing patent developments. This fuels anticipation of a potential acquisition, as investors weigh strategic board connections against the company's established lupus nephritis drug and promising autoimmune assets.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is actively trending as NVIDIA's recent filing revealed an exited position, sparking volatility and concern, while bulls maintain this was a strategic profit-take and point to strong institutional buying, continued AI infrastructure demand, and upcoming hyperscaler lease announcements.

Corsair Gaming, Inc. designs and supplies hardware components for personal computers. It operates through the Gamer and Creator Peripherals, and Gaming Components and Systems segments. The Gamer and Creator Peripherals segment offers gaming keyboards, mice, headsets, controllers, and gaming gear including capture cards, Stream Decks, USB microphones, studio accessories, and EpocCam software, as well as coaching and training services. The Gaming Components and Systems segment focuses on creating power supply units, or PSUs, cooling solutions, computer cases, DRAM modules, prebuilt, and custom-built gaming PCs. The company was founded by Andrew J. Paul in 1994 and is headquartered in Milpitas, CA.

Corsair Gaming Inc

Corsair Gaming is trending after reporting strong Q4 and full-year results, including an authorized $50 million share repurchase program, which has sparked a polarized debate among investors about whether the significant rally is sustainable or a manipulative pump and dump. The community is actively discussing the stock's potential for a short squeeze, its position to benefit from skyrocketing memory prices, and recent insider buying.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as a critical player in the evolving AI ecosystem, driven by its strategic partnership with Palantir, involvement in U.S. defense AI initiatives, and expansion into AI robotics. Amidst a broader market sell-off in AI, the community is debating whether the recent dip represents an exceptional buying opportunity, citing the company's strong fundamentals and vital role in training AI for various sectors, including emerging humanoid AI.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Aspire does not expect to conduct additional studies beyond its currently planned multicenter crossover clinical trial.</li><li>The firm said OTASA demonstrated faster and higher absorption of acetylsalicylic acid compared with chewed aspirin tablets.</li><li>The company said that&nbsp;&nbsp;Early safety evaluations showed the product was well tolerated, with no adverse events reported.</li></ul>Shares of Aspire Biopharma Holdings (ASBP) shot up 32% on Wednesday after the company said it received favorable feedback from the U.S. Food and Drug Administration (FDA) following a successful pre-investigational new drug (IND) meeting for OTASA, its high-dose sublingual (under-the-tongue) aspirin aimed at emergency treatment of suspected heart attacks.The FDA’s feedback supports a planned Section 505(b)(2) New Drug Application (NDA) submission in the second half of 2026, the company added.Based on the agency’s guidance, Aspire does not expect to conduct additional studies beyond its currently planned multicenter crossover clinical trial. The study will enroll 32 healthy volunteers and compare OTASA 162 mg with the current standard of care, two chewed 81 mg aspirin tablets, by measuring inhibition of serum thromboxane B2, a marker linked to blood clotting.The pre-IND submission was supported by encouraging pilot clinical data. Aspire said OTASA demonstrated faster and higher absorption of acetylsalicylic acid compared with chewed aspirin tablets. The sublingual formulation also achieved rapid platelet inhibition, reducing thromboxane B2 levels within the first two minutes after administration. Early safety evaluations showed the product was well tolerated, with no adverse events reported.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/ASBP">ASBP</a> remained in the ‘extremely bullish’ territory over the past 24 hours, amid ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/ASBP_jpg_d2fe432dd1.webp" alt="ASBP.jpg" width="906" height="105"><figcaption>&nbsp;</figcaption></figure>Users speculated that the company could already be engaged in licensing negotiations.<stembedurl>https://stocktwits.com/juned/message/641088627</stembedurl><stembedurl>https://stocktwits.com/Pennystockmadness/message/641086670</stembedurl><h2 class="st-heading-2">Stock Price</h2>The update and the subsequent rally in stock price come at a time when the company has been dealing with listing concerns stemming from its low share price. In November, investors approved a proposal allowing the board to implement a reverse stock split at a ratio of 1-for-5 to 1-for-40, within one year if needed.The company has also secured Nasdaq approval to remain listed, contingent on meeting minimum bid price and equity requirements by late January and mid-February 2026.At present, the stock is trading near the $0.14 mark.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/silver-falls-ahead-of-index-fund-rebalancing/cmxz3OLR420">Silver Tumbles 5% Amid Profit-Booking And&nbsp;Scheduled Reshuffling Of Commodity Index Funds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin –  Retail Expects Licensing Negotiations Soon

The FDA’s feedback supports a planned new drug application submission in the second half of 2026.

Equity

Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engages in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company was founded on February 2, 2025 and is headquartered in Estero, FL.

Aspire Biopharma Holdings Inc.

Fundamental

Technical

A mix of both

Some investors focus on company fundamentals like earnings, growth, and valuation. Others rely on price action, trends, and momentum. Many use a combination of both to guide their decisions. What do you use?

What type of analysis drives your investment decisions?

ASBP
Aspire Biopharma Holdings Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ASBP News

ASBPAspire Biopharma Holdings Inc